PEDIATRIC PATHOLOGY
Background: Recent evidence has implicated circulating angiogenic and antiangiogenic factors as the main mediators of the clinical symptoms of the maternal syndrome of preeclampsia. The placenta gross and microscopic examination is always used as confirmatory towards the clinical diagnosis of preeclampsia and cannot be used to exclude the diagnosis. However, in spite of the unique tissue biology of preeclampsia microscopic examination may not always yield diagnostic information. FT-IR is an imaging modality that allows for label-free imaging of tissue biochemistry to examine for biomolecular changes such as protein confirmation changes. Herein, we hypothesize that utilization of FT-IR spectroscopy will give a robust spectra of preeclampsia when compared to appropriate controls.
Design: We utilized a placenta tissue microarray (TMA) that consists of individual cores of the chorionic plate (P1), middle chorionic villi (P2), and basal plate (P3) for both preeclamptic (n = 38) and nonpreeclamptic tissue (n = 41). Samples with the clinical diagnosis of preeclampsia with chronic hypertension, preeclampsia with chronic hypertension and diabetes, preeclampsia with diabetes, and biological therapeutics were excluded from our analysis. Multivariate techniques such as principal component analysis and linear discrimination analysis were utilized to differentiate the two groups.
Results: Analysis of P1, P2, and P3 was performed independent of one another. We collected FT-IR data from the TMA and extracted biochemical signatures from the placenta tissue. P3 showed the best biochemical distinction between normal (n = 27) and preeclamptic (n = 19) placenta, with a misclassification rate of 7 out of 46 samples (Fig 1) . P1 showed the poor biochemical distinction between normal (n = 33) and preeclamptic (n = 34) placenta, with a misclassification rate of 20 out of 67 samples (Fig 2A) . P2 also demonstrated weak biochemical distinction between normal (n = 28) and preeclamptic (n = 22) placenta, with a misclassification rate of 15 out of 50 samples (Fig 2B) .
Conclusions: FT-IR is an emerging tool for biomarkers analysis of formalin-fixed paraffin-embedded tissue in a nondestructive manner. Our data suggest that the basal plate show the best biochemical distinction between preeclamptic versus nonpreeclamptic placenta. The tissue core from P3, which consists of both chorionic villi and decidualized endometrium, was the best predictor of preeclampsia. However, spectra changes cannot be reliably discern from both P1 and P2. Indiana Univ/ Medicine, Indianapolis, IN Background: Biliary atresia (BA) is characterized histologically by features that reflect severe biliary obstruction at the hilum. There is an intense ductular reaction comprised of proliferating bile ductules associated with neutrophils and portal fibrosis. The bile ductules appear dilated and may contain bile plugs. Although hepatic arterioles are not considered to be an integral part of this response, we (and others, anecdotally) have noticed that they appear prominent and thickened. In this context, it is pertinent that the hepatic artery represents the sole arterial supply to the biliary tract, which also explains the close anatomical proximity and perhaps, the nearly identical diameters of the two structures. We systematically studied the dimensions of paired hepatic arterioles and bile ducts, as well as the ratios of bile duct to hepatic artery diameters (BD:HA) in BA, and compared them to an age matched group of infants with neonatal hepatitis.
Design: The pathology database was queried to identify liver core and wedge biopsies performed on infants less than 12 weeks of age with BA (study group) and neonatal hepatitis (control group). Morphometric analysis was performed on 3 μ-thick sections from formalin fixed, paraffin embedded tissue utilizing a calibrated Nikon DS Camera Control Unit DS-L1 by a pathologist who was blinded to the diagnoses. Cross-sectional profiles of paired hepatic arterioles and bile ducts were identified on trichrome-stained slides. Tangential profiles of hepatic arteries and bile ducts, and non-paired hepatic arterioles and bile ducts were excluded. For each hepatic arteriole, the widest cross-sectional and luminal diameters were measured, and used to calculate the arteriolar wall thickness. The widest cross-sectional diameter of the accompanying bile duct was measured. The ratio of the cross-sectional diameters of the bile duct to hepatic artery (BD:HA) was calculated for each pair.
Results: Results are shown in Table 1 .
Comparison of bile ducts and hepatic arterioles in biliary atresia to neonatal hepatitis Background: Clear cell sarcoma of the kidney (CCSK) harbors internal tandem duplications in the last exon of the BCOR gene in over 90% of cases, with a smaller subset harboring YWHAE-NUTM2B/E or BCOR-CCNB3 gene fusions. All of these genetic abnormalities result in a transcriptional signature characterized by high BCOR mRNA expression. Nuclear labeling for BCOR by immunohistochemistry (IHC) has been demonstrated to be a highly sensitive marker of CCSK (Am J Surg Pathol 2016; 40:1670 -1678 . The specificity of BCOR IHC in the context of pediatric renal neoplasia has not previously been studied.
Design:
We evaluated whole sections from 62 neoplasms, including 32 Wilms tumors, 10 congenital mesoblastic nephromas (CMN) (1 classic, 5 cellular, 4 mixed), 8 CCSK, 8 metanephric stromal tumors (MST), 2 rhabdoid tumors of the kidney (RTK), 1 renal PNET and 1 sclerosing epithelioid fibrosarcoma (SEF). We performed immunohistochemistry for BCOR using clone C-10 (SC-514576; Santa Cruz, Dallas TX) generated against the N-terminus of BCOR at a dilution of 1:150 as done previously. Tumors were evaluated on the basis of intensity of labeling (strong, moderate, weak, or negative) and the percentage of positive neoplastic cells. Only nuclear labeling was counted. Neoplasms with less than 10% labeling were considered minimally positive, neoplasms with moderate to strong labeling in 10-50% of neoplastic cells were considered focally positive, while neoplasms with moderate to strong labeling in greater than 50% of cells were considered diffusely positive. 
Results
Conclusions: Diffuse nuclear IHC labeling for BCOR using previously published conditions is highly sensitive and specific for the diagnosis of CCSK in the setting of pediatric renal neoplasia. Nonetheless, caution is required (particularly in limited biopsy material) as other neoplasms may occasionally show focal labeling. University of Virginia, Charlottesville, VA Background: Ciliary dysmotility is detrimental to mucociliary clearance and may cause significant respiratory morbidity and mortality. We examined the clinical features of children without inherited primary ciliary dyskinesia who had ciliary immobility (CI) on bronchoscopic specimens. The primary purpose of the study was to evaluate in cross-section the features of children with (CM) and without intact cilia.
Design:
Children (n=211) with refractory wheezing or asthma underwent diagnostic bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings. Fresh bronchial epithelial cells submitted in RPMI underwent ciliary motion evaluation using real time microscopy by a cytology fellow followed by a faculty cytopathologist.
Results: Eighteen children (8.5%) with CI were more likely to be pre-school age (p < 0.05). There were no differences by sex or race. Structural anomalies (laryngeal clefts and trachea-or bronchomalacia) occured in 61% vs. 36% of CI vs. CM respectively (p = 0.03). 30% of non-asthmatic children lacked motility compared to 6% of asthmatics (p = 0.001). Only 2 CM cases had ciliary ultrastructural examination; one had no abnormalities and the other had loss of inner dynein arms only. There was no difference in BAL granulocyte phenotype in CI and CM cases. There was a trend towards lower total blood eosinophilia, but no difference in atopy in the two groups. There was a significant difference in viral detection (59% and 32% in CI and CM cases respectively, p=0.02). 44% of CI cases had positive rhinovirus transcripts versus 27% of CM (p>0.05). 19% of CM were positive for non-enteroviruses versus 4% of CI (p = 0.01). An unpaired t-test comparing outcomes in the 2 groups showed significant differences: CI children were on average 4 years younger, had lower total IgE, and fewer BAL eosinophils (p < 0.05 for all).
Conclusions: 8.5% of children who undergo bronchoscopy for refractory respiratory symptoms lack ciliary motility. These children are younger, have an almost 2-fold higher prevalence of structural anomalies, less asthma and less allergen sensitization, but a strikingly higher prevalence of lower respiratory tract viral infections, primarily non-enteroviruses. Ciliary motility studies in this group of patients with likely acquired/transient airway malacia can help guide treatment. This study serves as a reminder that while ciliary motility studies are not specific for inherited primary ciliary dysplasia, they can provide useful clinical information in other patients. Background: Embryonal (undifferentiated) sarcoma of the liver (ES) is a rare, aggressive pediatric malignancy. The immunohistochemical profile of these tumors is often nonspecific with a variable staining pattern. The molecular profile of these tumors is not well-characterized. The aim of this study is to expand and better define the molecular profile of these tumors.
Design: Following IRB approval, four cases of ES in the pediatric age group (0 to 18 years) were identified in our intradepartmental cross-files within the last 20 years. Columbia Combined Cancer Panel (CCCP), a targeted exome sequencing assay, with copy number variant analysis (CNVA) was performed on the archival formalin-fixed paraffin-embedded tissue of tumor/normal pairs in all four cases.
Results: Two of four cases showed different TP53 mutations, while one case showed PIK3C2G mutation, and no mutation was found in the fourth case. Our cases showed amplifications and deletions of variable genes, as listed in Table 1 Aside from typical hematogenous metastases, such as bone and lung lesions, we have also observed frequent perineural tumor dissemination manifested by the presence of migratory ES cells along the nerves adjacent to the primary tumors. This phenomenon was associated with formation of recurrent tumors at the amputation sites, as well as paravertebral tumors at lumbo-sacral, thoracic and cervical levels. These tumors showed perineural and sympathetic ganglion compromise. Interestingly, the level of perineural invasion (PNI) was dependent on the expression of neuropeptide Y (NPY) in ES cells. NPY is a neuronal protein released from peripheral sympathetic neurons, but also highly expressed in ES cells along with its receptors. The xenografts derived from ES cell lines not releasing endogenous NPY (TC71, TC32) exhibited frequent PNI in tumor-bearing limbs, as well as a high number of recurrent tumors in the surgery site and paravertebral tumors (70% and 100% of mice with evidence of PNI for TC71 and TC32 xenografts, respectively). These processes were less common in ES xenografts derived from NPY-rich SK-ES cells (35% of mice with signs of PNI). In line with these observations, NPY knockdown in SK-ES xenografts drastically accelerated formation of spinal tumors (60% of mice). Notably, in 40% of mice bearing SK-ES NPY shRNA xenografts the paravertebral tumors developed before the primary tumor growth was detectable at the site of ES cell injection.
Altogether, our data indicate that lack of endogenous peptide in ES cells expressing high levels of its receptors triggers chemotactic effects of NPY released from neighboring peripheral nerves, facilitating PNI. Further studies are required to determine which of NPY receptors is responsible for its chemotactic properties. Blocking pathways responsible for PNI in ES, e.g. NPY receptors, may lead to development of novel therapies preventing disease dissemination and recurrence. is introducing a new provisional entity "myeloid neoplasms with germline predisposition", which covers these IBMFS to some extent, the association of IBMFS with myeloid neoplasms has not been well studied, due to rare cases and under-recognition of underlying marrow failure before MDS/AML develops.
Design: A retrospective chart review of pediatric (0-21 years of age) patient records from 2012-2017 at our institution was performed.
Patients were identified based on clinical diagnoses of Schwachman Diamond Syndrome, Fanconi anemia, thrombocytopenia absent radii syndrome (TAR), Diamond-Blackfan anemia, and dyskeratosis congenita. Pathology reports, flow cytometric studies, cytogenetics, and clinical data were reviewed.
Results: Fifty-two patients with a presumptive diagnosis of IBMFS were identified with 3/52 (6%) patients progressing to MDS/AML. An initial diagnosis of MDS/AML was made at ages 8, 11, and 18 for patients 1-3, respectively. The three patients met the current WHO diagnostic criteria for a myeloid neoplasm with germ line predisposition. The presenting symptoms included fever, pancytopenia, and weight loss. The blast percentage in the bone marrow core biopsy for cases 1 and 2 ranged from 10-15% while the blast percentage in case 3 was 15-20%. (PLA2R) is implicated in the pathogenesis of primary MGN in adults. Since the discovery, immunohistochemistry (IHC) has been increasingly employed in the diagnosis of primary MGN by detecting PLA2R antigens in glomerular subepithelial deposits. However, the status of PLA2R in pediatric MGN, a relatively rare disorder, is not well established. In this study, we present a multi-institutional experience of PLA2R expression in primary versus secondary MGN in a pediatric population.
Design: 36 pediatric renal cases (age ≤19 years) with diagnosis of MGN were retrospectively collected from two different institutions (Georgetown University Hospital and Children's National Medical Center, Washington DC).IHC was performed on tissue sections using PLA2R monoclonal antibody (CL0474, 1:1500 dilution) and IgG4 monoclonal antibody (HP6025, 1:500 dilution). PLA2R and IgG4 results were scored blindly, then compared with clinical, morphologic, immunofluorescence (IF) and electron microscopy (EM) findings in primary and secondary MGN.
Results: Out of 36 cases of MGN, 3 met the criteria of primary MGN (without any known etiology). Out of 33 secondary MGN, 27 cases were lupus nephritis (bona fide secondary MGN) and the remaining 6 cases were clinically classified as secondary MGN due to concurrent non-lupus medical conditions. PLA2R was positive (glomerular basement membrane staining) in all 3 primary cases (100%, Fisher's exact test, p < 0.03), 5 of 6 non-lupus secondary MGN (83%, Fisher's exact test, p <0.01), and 4 of 27 (15%) lupus secondary MGN (see diagram 1). On comparison with morphologic, IF and EM findings, all five PLA2R+ non-lupus secondary MGN showed features resembling primary rather than secondary MGN without a "full-house IF pattern" and deposits confined to subepithelium on EM (see table 1). IgG4 was negative in all pediatric MGN. Background: Congenital leukemia (CL), defined as leukemia occurring in a neonate, is a specific category within infantile leukemias. The clinicopathologic features for infantile leukemias other than CL seem to vary with a significant fraction resembling CL.
Design: With institutional approval, 79 cases of infantile leukemia were retrieved from our pathology database, and their clinicopathological findings were retrospectively evaluated.
Results: Of 79 cases, 36 were male, and 43 were female patients. 93.3% of the patients were born full term with birth weight ranging from 2.6 to 3.5 kg (median=3.1 kg), while 6.7% wereborn prematurally (median 34 weeks) with median birth weight of 3.5 kg. Patients presented with symptoms of leukemia at ages ranging from the first day of birth to 16 months, with median age of 5 months. 8 cases were diagnosed within 30 days of birth, consistent with CL. The majority of patients presented with signs and symptoms including skin bruising, leukocytosis, anemia/thrombocytopenia, and/or splenomegaly. Types of leukemia included B-lymphoblastic leukemia (B-ALL) in 50 (63%) cases, acute myeloid leukemia (AML) in 24 (30%) cases, T-lymphoblastic leukemia (T-ALL) in 3 (4%) cases, and other myeloid neoplasms in 2 (3%) cases. Cytogenetic studies revealed clonal abnormalities in 71 (92%) cases, including MLL (11q23) gene rearrangement in 47 (66%), hyperdiploidy in 8 (11%), and other abnormalities in 16 (23%) cases. Interestingly, among B-ALL patients, when plotting against age, the MLL gene rearrangement inversely correlated with age (months), with abrupt decline at 8 months (Figure 1) . Most of the patients received treatments corresponding to leukemia type. Out of 79 patients, with median follow up of 24 months, 57% died of disease progression, with average overall survival of 95+13 months. When stratified by age, the group of ≤8 months had an average overall survival (49+9 months) which was significantly shorter than the group of ≥8 months (131+21 months; P<0.05) (Figure 2 ).
Conclusions:
Infantile leukemia demonstrates a unique cytogenetic profile, featuring a high fraction of MLL gene rearrangements, particularly those occurring within 8 months of life. The clinical outcome of infantile leukemia is also extremely poor despite vigorous treatment. CL, as a special subcategory of this disease, has even more dismal outcomes, and the biological behavior remains similar with age until 8 months. Additional large cohort studies are needed to further classify this disease entity. Rhode Island Hospital, Providence, RI Background: A subset of primitive sarcomas (PrSs) with round cell and/or spindle cell morphology resembling Ewing sarcoma/ primitive neuroectodermal tumors (EWS/PNETs) but lacking the characteristic EWSR1 rearrangement have been found to harbor rearrangement of the CIC gene. These CIC-rearranged (CIC+) sarcomas are the most common form of EWSR1 negative Ewing-like sarcomas and fusion with the DUX4 gene occur in the vast majority of cases. Recently immunohistochemical (IHC) expression of DUX4 using a commercially available monoclonal antibody (Mab) to the C-terminus of the human DUX4 protein (clone P4H2) was reported to be highly sensitive (100%) and specific (100%) in 5 CIC-DUX4 cases compared to 76 other small round cell tumors.
Design: Archival cases of CIC+ sarcomas (8 genomically proven CIC-DUX4+, and 1 CIC+ by FISH), EWS/PNETs (17), BCOR-CCNB3 sarcomas (2), desmoplastic small round cell tumors (DSRCTs; 12), rhabdomyosarcomas (RMS; 19), and synovial sarcomas (SS;10) fulfilling IHC and molecular criteria were included in this study. DUX4 IHC staining with the same Mab at a dilution of 1:200 was performed on whole sections of biopsies or resections with a minimum of one thousand neoplastic cells available for scoring with appropriate positive and negative controls. Semiquantitive scoring of IHC staining was based on intensity and extent of nuclear staining: 0, 0% of cells positive; 1+, weak staining or <10% of cells positive; 2+,10-50% of cells moderately to strongly positive, and 3+, >50% of cells moderately or strongly positive. A score of 2+ or 3+ was considered positive.
Results: DUX4 IHC expression in this study is summarized in the Table. The 6 CIC+ sarcomas that were DUX4+ included a FISH+ needle biopsy case (strong, >75% ), and 5 of the CIC-DUX4+ cases (1 case with 40-50% moderate, 1 case with 50-75% moderate, 1 case with >75% moderate and 2 cases with > 75% strong staining). The other positive PrSs were 1 BCOR-CCNB3 tumor (40-50%, moderate), 1 EWS/ PNET (10-20%, moderate) and 1 DSRCT (20-25%, moderate). Overall the sensitivity was 66.7%, specificity was 95%, positive predictive value was 66.7% and negative predictive value was 95%. Background: Chondroblastoma is a benign cartilaginous lesion that typically presents in childhood and shows histologic overlap with other benign and malignant bone tumors. Diagnostic immunohistochemistry (IHC) for chondroblastoma has previously been limited to S100, a nonspecific stain. The H3 K36M mutated oncohistone has been described as a more specific marker of chondroblastoma and giant cell tumors and is part of a family of altered histones that define the molecular signatures in various pediatric malignancies including glioblastomas. An IHC antibody directed against the H3K36M mutation may assist in the diagnosis of these lesions.
Design: A total of 108 cases including 57 chondroblastomas, 4 chondromyxoid fibromas, 17 chondrosarcomas, 10 giant cell tumors of bone (GCT), 10 osteosarcomas and 10 aneurysmal bone cysts (ABC) were selected from our pathology archives. Anonymized data including patient age, gender, lesion location, final diagnosis, and decalcification were recorded. Tissue sections from all cases underwent IHC staining for anti-Histone H3K36M mutant protein (Millipore, Temecula CA). Immunoreactivity was graded as 4 (strong) if over 50% of cells exhibited nuclear staining, 3 (moderate) if 10-49% of cells showed staining, 2 (weak or focal) if staining was faint or present in less than 10% of cells, 1 if staining was barely perceptible but present at 10x, and 0 if staining was not visible above background.
Results: A summary of the IHC results is presented in Table 1 . The commercially available H3K36M mutant antibody produced readily interpretable nuclear immunoreactivity in positive cases, although the intensity varied. Some background cytoplasmic staining was present in both chondroblastoma and other bone tumors. Using our scoring system, H3K36M mutant staining was minimal or absent in the other malignant and benign bone tumors examined. Moreover, H3K36M mutant was highly sensitive (95%) and specific (94%) for chondroblastoma and displayed a strong positive predictive value (95%) and negative predictive value (94%). (Neuroscience 2017; 354:196-207) . Because an independent biomarker for prediction of seizurefree outcome in FCDII epilepsy patients has not been validated previously, we propose to evaluate Akt overexpression, using a novel immunohistochemical (IHC) technique, as a biomarker for predicting seizure-free outcome in children with pathology-confirmed FCDII.
Design: This retrospective study reviewed patients who had epilepsy surgery from 2008-2012. Institutional Review Board approval was obtained. Inclusion criteria were: age <18y, pathology-confirmed FCDIIa or FCDIIb, and follow-up evaluation (≥1y post surgery). Exclusion criteria were: FCD Types I or III, dual pathology, and hemispherectomy. IHC methods, published previously in JNEN 2013;79:884-891, determined the highest density/high power field (hpf,×40) of Akt1-positive neurons in resected cortical tissue. Receiver operator characteristic (ROC) analysis evaluated the validity of Akt1-positive neuron count for prediction of seizure-free outcome (ILAE classification 1). The IHC cutoff was selected using the highest Youden index (Sensitivity+Specificity-1).
Results: A total of 25 patients with FCDII were identified, including 8 FCDIIa and 5 FCDIIb, who were seizure-free, and 12 who were not seizure-free. Clinical characteristics were similar for seizure-free and non-seizure-free groups (Table 1 ). The Akt1-positive neuron count was significantly increased in the seizure-free study group (Table 1) . ROC curve analysis had the highest predictive probability for seizure-free outcome at ≥7 Akt1-positive neurons/hpf. At that cutoff the following results were obtained: sensitivity=0.769, specificity=0.750, PPV=0.769, NPV=0.750, accuracy=0.760, and area-under-the-ROC curve=0.756 (P=0.007). The predicted probability graph (Figure 1 ) and ROC curve model (Figure 2) Background: The significance of lymphocytic esophagitis (LyE) in children is poorly defined. Here we report the largest series of LyE in children with detailed description of the clinical and follow up findings.
Design: All esophageal biopsies performed on children (≤18 years-old) from January 2005 to May 2015 were reviewed. Only cases with ≥20 lymphocytes/high-power field and rare eosinophils (≤2) are included. Demographics, endoscopic findings and follow-up are retrieved from pathology reports and medical records in accordance with the institutional research board guidelines. Immunohistochemistry for CD3, CD20, CD4 and CD8 was performed. Lymphocytic count was generated by counting the numbers of lymphocytes at 40X in a single hot spot.
Results: Twenty-four patients fulfilled the search criteria (age range: 1-17.5 years; mean: 6.9 years). They consisted of 11 males (age range: 1-17.5; mean: 6.9 years) and 13 females (age range: 2-16.5 years; mean: 6.9 years). The most common presentation was dysphagia (33.3%) followed by reflux (29.2%), abdominal pain (29.2%), and nausea and vomiting (8.3%). Esophageal endoscopic findings ranged from normal to erosive esophagitis. Ileal and colonic endoscopy ranged from normal to severe active inflammation.
The mean number of lymphocytes was 40.4 (range 21-71 lymphocytes). There was correlation between the number of lymphocytes and a particular final diagnosis. In addition, there was no difference in the number of lymphocytes between males and females. The vast majority of lymphocytes expressed CD3 and, to a lesser degree, CD8. A minority expressed CD4 and CD20. There was no correlation between the immunophenotype and a particular diagnosis.
Follow-up showed that 7 patients were diagnosed with gastroesophageal reflux disorder, 7 patients with eosinophilic esophagitis, 3 patients with Crohn's disease, 1 patient with celiac disease, 1 patient with ulcerative colitis, and 3 patients with gastritis. Follow-up in 3 patients did not disclose any particular entity and, therefore, these patients were diagnosed with LyE.
Conclusions: Lymphocytes esophagitis in children remains a poorly defined entity. Our study suggests that a particular diagnosis is often not apparent at the onset of LyE and, therefore, a regular follow-up is required in order to identify the underlying disease. Our results also show that LyE is not associated with a particular disease but rather it represents a prelude to other better defined entities. 
Genomic Landscape of Pediatric Hepatocellular Carcinoma

University of Kiel
Background: Hepatocellular carcinomas (HCC) of childhood are rare neoplams. Their pathogenesis is believed to be different from HCC in adulthood. The differential diagnosis from hepatoblastoma (HBL) is important because of worse prognosis of pediatric HCC (pHCC) and different treatment approaches. However, the diagnosis by conventional histological analysis may be difficult in some cases. Informations on chromosomal alterations in pHCC are lacking. The aim of this study was to identify recurrent chromosomal aberrations, mRNA expression and epigenetic signatures in a larger cohort of pHCC and compare it to HBL to identify characteristic genomic alterations of pHCC.
Design: Genomic DNA was extracted from FFPE and fresh frozen samples of a cohort of 44 pHCC including 4 cases of the fibrolamellar subtype and 3 cases with partial fibrolamellar differentiation from the archives of the German Pediatric Tumor Registry, University of Kiel. Genome-wide copy analysis was performed by molecular inversion profiling. GISTIC analysis was done to identify significant large and focal aberrations. Epigenetic signatures were studies using methylation arrays, mRNA expression analyzed using HTA2.0 expression arrays. Protein expression and recurrent copy number alterations were validated using tissue microarrays.
Results: Most frequent copy number alterations were gains of chromosome 1q (68%), 2q (34%), 20 (34%), 6p (30%),19q (27%) and 8q (27%) and losses of chromosomal regions 1p (52%) and 4q (41%). In addition, GISTIC analysis identified several significant fokal alterations including losses of the AXIN1 tumor suppressor locus on 15q26 in 41% of cases. 6/34 pHCC lacked any larger chromosomal imbalances. Of note, 5 of these 6 genomically stable tumors showed fibrolamellar differentiation. When pHCC were compared to HBL, both entities shared similar alterations including gains if 1q, 2, 8 and 20, but losses of 1p and 4q and gains of 19q were significantly more frequent in pHCC. Cluster analysis of expression and methylation data did not separate a specific pHCC cluster from HBL. Gene set enrichment analysis identified WNT signalling and ribosome profiles to be enriched in pHCC when compared to fetal fetal liver.
Conclusions: This genome-wide copy number, epigenetic and mRNA expression analysis of pHCC uncovered characteristic alterations and signatures which showed similarities to HBL but also indicated a specific pathogenesis of pHCC. Specific genetic alterations may help in the differential diagnosis of these tumors. Design: A cohort of 37 infants with clinically suspected hypoxic ischemic injury at birth was identified. Infants with evidence of cerebrovascular infarction by imaging or clinical examination were excluded from the study. Placentas from all cases were examined for pathology. Fetal vascular malperfusion (FVM) was diagnosed and graded based on the Amsterdam Placental Workshop Group Consensus Statement.
Results: Clinical data was available for 34 children, with a mean followup time of 3.75 years for non-deceased patients. 14 infants (38%) underwent therapeutic hypothermia for hypoxic ischemic encephalopathy (HIE). Autopsy data was available in 5 of the 6 deaths. Clinical outcomes included severe developmental delay or cerebral palsy in 6 children (17%), death in 6 children (17%), mild motor and/or sensory delays in 12 children (35%), and no significant abnormality in 7 children (20%), mild behavior issues in 2 children (6%), and seizures as the only sequelae in 1 child (3%). Rates of high grade FVM were significantly increased with severe developmental delay or cerebral palsy when compared with the normal outcome group (P = 0.0133). High grade FVM was present in 4 of 6 children with severe developmental delays or cerebral palsy, 3 of 12 children with mild motor and/or sensory delays, and none of the 7 children with normal outcome. Low grade FVM was not associated with clinical outcome and was present in one child with mild developmental delay and one normal child. Rates of central-type hypoxic ischemic injury on imaging (i.e. injury preferentially focused in the deep gray matter) were significantly increased in children with severe developmental delays or cerebral palsy (3 of 6 children) compared with rates in children with mild outcomes (1 of 12 children) (P = 0.0380). The proportion of placentas under the 10 th percentile for gestational age was not statically different across the various clinical outcome groups.
Conclusions: In summary, imaging findings and placental pathology were collected in a cohort of children with suspected hypoxic ischemic injury and correlated to clinical outcomes. We found that high grade FVM was associated with increased neurological morbidity.
DNA Methylation Analysis Defines Two Distinct
Subgroups of Clear Cell Sarcoma of the Kidney Clear cell sarcoma of the kidney (CCSK) is the second most common pediatric renal malignancy and represents approximately 3 to 5% of all renal tumors in children. Several histologic variants of CCSK have been described, and to date, two distinct molecular alterations have been identified. Approximately 80% of CCSKs harbor B-cell CLL/ lymphoma 6 (BCL6)-interacting co-repressor (BCOR) gene internal tandem duplication (ITD), and an additional 10% are positive for YWHAE-NUTM2B/E fusion. The remaining CCSKs are negative for both BCOR-ITD and YWHAE-NUTM2B/E fusion-the so-called doublenegative subcategory. We hypothesize that CCSK is composed of distinct molecular subgroups and that these subgroups could be distinguished by their unique genomic alterations, epigenetic signatures, and immunophenotype.
A cohort of 30 CSSK was reviewed and stained with selected immunohistochemical stains (BCOR, WT-1, INI-1, YAP-1, Cyclin D-1, EGFR, BCL-6, H3K27me3, and p53). All cases were evaluated by Interphase Fluorescence In Situ Hybridization (iFISH) for YWHAE-NUTM2B/E gene rearrangement and via targeted PCR for BCOR-ITD and Epidermal growth factor receptor (EGFR)-ITD. The tumor-specific methylation signature and CNAs were derived using the Illumina Infinium 850K methylation array. Anaplastic and non-anaplastic Wilms tumors were included among the control samples.
Using unsupervised cluster analysis of the methylation data, the CCSKs cluster into two distinct subgroups. The largest group includes the BCOR-ITD positive CCSKs and show a comparatively stable genome. The second distinct cluster contains the YWHAE generearranged and double negative tumors. This cluster is characterized by more frequent CNAs and uniformly expresses cytoplasmic WT1. One double-negative CCSK harbored an EGFR-ITD.
Conclusions: Our data suggest that CCSK represents two molecularly distinct subgroups, and supports the concept that BCOR-ITD and YWHAE-NUTM2B/E fusion are mutually exclusive. The YWHAE-NUTM2B/E rearranged and double negative cases are closely related, and can be identified by their distinct diffuse cytoplasmic WT1 expression. Whether these subgroups have prognostic significance or demonstrate differences in clinical behavior is yet to be determined.
2001 High expression of pAKT and pmTOR in multicystic renal dysplasia Background: Multicystic renal dysplasia is congenital cystic anomaly of the kidney caused by abnormal metanephric differentiation associate with immature tubules surrounded by mesenchymal collars and islands of immature mesenchyme are present between the cysts. The PI3K-Akt-mTOR signaling pathway is a key regulator of normal cellular processes involved in cell growth, proliferation, motility, survival, and apoptosis. Activation of the PI3K-Akt-mTOR pathway results in the survival and proliferation of tumor cells in many human cancers.
The aim of this study is to analyse the topographic expression of Phospho-AKT and Phospho-mTOR in normal renal development and in multicystic dysplastic kidney.
Design: The samples came from Grenoble University Teaching Hospital legally declared collection of embedded tissue sections collected after autopsy for perinatal and infant death performed for a diagnostic purpose. Written consent was obtained from the parents or guardians at the time of the request for autopsy authorization and for research authorization on normal and abnormal development. 17 cases of normal fetal kidneys of different ages of development used for control and 13 cases of pathological kidneys with MCDK were mainly analyzed by immunohistochemistry in order to evaluate the expression of Phospho-AKT (S473) and Phospho-mTOR.
Results: Phospho-AKT and Phospho-mTOR are early expressed in normal renal development and in identical manner for every structure derived from the ureteric bud such as collecting ducts and urothelium. Later, their expressions differ according to the needs of cell proliferation and differentiation over time by becoming more selective.
In multicystic renal dysplasia, Phospho-AKT and Phospho-mTOR were constantly present with high cytoplasmic expression in cystic epithelium, loose mesenchyme. In primitive tubes, a high expression of both proteins was found in epthelial cells but not in adjacent mesenchyma.
1 .
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University of Michigan, Ann Arbor, MI Background: Recurring cytogenetic abnormalities play important roles in the diagnosis and prognosis of pediatric solid tumors. However, classic cytogenetics is often challenging due to tissue culture failure, treatment effect, or inadequate sampling. Whole-genome array analysis (WGA) overcomes the need of cell culture and only uses small amount of DNA. It was implemented for the detection of cryptic copy number abnormalities and copy-neutral loss of heterozygosity for both hematological malignancies and pediatric solid tumors in our institution.
Design: We retrospectively reviewed diagnostic samples obtained from pediatric solid tumors with cytogenetic tests between March 2015 -August 2017. WGA using Affymetrix CytoScan platform were performed in a total of 157 samples, and conventional cytogenetics was performed in 146 of them. We compared array results with karyotype or FISH results and correlated with histological diagnoses.
Results: A variety of solid tumors were submitted for cytogenetic tests, the most common ones included neuroblastomas (N=21), sarcomas (N=18), Wilms tumors (N=17), teratoma (N=16), and brain tumors (N=15). One hundred and eighteen (75.2%) specimens had at least one copy number aberrations or region of loss of heterozygosity detected by WGA. Genetic abnormalities that were associated with diagnosis, prognosis or therapy were observed in 99 of them (63.1%). Genetic results indicative of a malignant process were observed in 3 cases of benign lesion; genetic results not consistent with original histological diagnosis were noted in an Ewing sarcoma and two brain tumors. Conventional cytogenetics was performed in 146 samples, 58 of them (39.7%) had an abnormal karyotype or abnormal FISH results, and the remaining had a normal karyotype (22.6%) or inadequate cells for cytogenetic analysis (37.7%). Abnormal array results were detected in 91.3% of the samples with an abnormal karyotype, in 39% of the samples with a normal karyotype, and in 76.4% of the samples with an inadequate cytogenetic analysis.
Conclusions: WGA improved detection of cytogenetic abnormality rate from 39.7% to 75.2%. It provided clinically relevant results in over 60% of the tumors, and improved diagnosis, prognosis and treatment of pediatric solid tumors. We suggest that WGA be considered as the first tier cytogenetic test in most pediatric solid tumors, especially when material is limited, with the exception when balanced rearrangements are the common recurring abnormalities. 
University of Iowa Hospitals and Clinics
Background: Meta-iodobenzylguanidine (MIBG), a norepinephrine analogue, is concentrated in cells of the autonomic nervous system and cognate tumors. MIBG-based nuclear medicine imaging is routinely utilized to stage neuroblastoma (NB) patients at initial clinical presentation, and patients with primary resistant or recurrent disease may be treated with MIBG-based radionuclide therapy. The G protein-coupled receptor SSTR2A is highly expressed by neuroendocrine tissues and tumors, and the chemokine receptor CXCR4 is highly expressed by poorly differentiated neuroendocrine carcinomas. SSTR2A and CXCR4-based imaging and radionuclide therapy are being pursued in adult neuroendocrine tumors. Expression was evaluated for intensity (0-3+) and extent (0-100%) with an H-score calculated (intensity*extent). Fisher's exact test was used with p<0.05 considered significant.
Results: SSTR2A was expressed by 49% of NBTs and 21% of Wilms tumors, though very weakly so in the latter. CXCR4 was expressed by 22% of NBTs and 45% of Wilms tumors. Detailed expression data are presented in the Table. Degree of differentiation did not appear to influence the frequency of SSTR2A expression (44% in U/PD vs. 58% in D/GNB/MG; p=0.32), but CXCR4-positivity was largely restricted to more primitive tumors (32% U/PD vs. 8% of D/GNB/MG; p=0.034).
Conclusions: SSTR2A is expressed by half of NBTs regardless of differentiation, representing a potential therapeutic target in advanced disease. CXCR4 is preferentially expressed in more primitive NBTs, in which it again represents a potential therapeutic target. Of note, nearly half of Wilms tumors expressed CXCR4 (at similar levels as in NBTs) with potential diagnostic and therapeutic implications. Background: Pediatric ovarian diseases encompass a wide range of pathologic processes, which differ significantly in behavior and prognosis. For example, while malignant ovarian tumors may be life threatening, both malignant and benign ovarian tumors may cause significant morbidity, such as potential infertility. Thus, prompt and accurate diagnosis is essential for appropriate management. The purpose of this study is to describe the spectrum and incidence of ovarian pathology at our institution over the past 20 years.
Design: After approval by the Institutional Review Board, a review of all pathology reports from a large metropolitan pediatric hospital, from January 1, 1996 to April 1, 2017 was conducted. Inclusion criteria were specimens containing ovarian tissue from female patients ranging from birth to age 21 years. Any cases from intersex patients were excluded.
Results: Cases were retrieved for 595 female patients with 729 specimens. The age ranged from 1 day to 19 years (mean 11.8 years, median 13 years). As shown in the pie chart [FIGURE 1], neoplasms comprised the majority of the diagnoses. The most common benign neoplasm was mature teratoma (n=174, 24.4% of all cases) followed by serous cystadenoma (n=42, 5.9%). The most common malignant neoplasm was malignant mixed germ cell tumor (n=14, 2%), followed by juvenile granulosa cell tumor and Sertoli-Leydig cell tumor (each n=8, 1.1%). Metastatic neoplasms included 1 case of anaplastic Wilms tumor and 2 cases of lymphoblastic leukemia/lymphoma. The most common benign cyst was follicular cyst/ cystic follicle (n=98, 13.7%), followed by corpus luteum cyst (n=74, 10.4%) and paratubal cyst (n=28, 3.9%). Inflammation and/or reactive changes were seen in 18 cases (2.5%). Torsion (or consistent with torsion) was the most common diagnosis (n=88, 12.3%) in the miscellaneous category. Interestingly, 37 specimens (5.2%) demonstrated no significant histopathologic abnormality.
Conclusions: This is one of the largest clinico-pathologic studies of pediatric ovarian lesions. Ovarian lesions are not uncommon in children and require special attention due to the relatively wide differential diagnoses and the potential significant consequences later in adulthood. Similar studies from other pediatric institutions from around the world may illustrate any geographic or ethnic variations in pediatric ovarian pathology. Background: Glial tumors are the most frequent CNS tumors in childhood. Historically, tumor classification has relied upon histology and immunohistochemistry. Recently, molecular alterations have improved the ability for glial tumors classification and prognostication. The 2016 WHO CNS tumor classification incorporated molecular parameters modifying some of the glial categories. It is to be determined whether or not this revision provides more accurate riskgroup classification, prognostication, and its impact in therapy.
Design:
We assessed 192 tumors. Initial diagnosis was done according to the 2000 and 2007 WHO classifications. All cases were histologically re-evaluated. Additionally, immunohistochemical, cytogenetic and molecular analysis were performed following the WHO 2016 classification recommendations. Our main objective was to identify the potential impact of the new classification in our retrospective cohort in terms of risk-group classification, prognosis and therapeutic approach.
Results: The initial diagnosis according to the previous editions of the WHO classification included: low-grade glioma (LGG) 121; high-grade glioma (HGG) 30; glioneuronal tumor (GNT) 28; diffuse midline glioma (DIPG) 2; gliomatosis cerebri (GC) 2; high-grade neuroepithelial tumor (HGNET) 7; insufficient material 2. Following reassessment using the new WHO 2016 criteria, the tumors were regrouped as follow: LGG 112; HGG 12; GNT 32; DIPG 0; GC 0; HGNET 5; HGG-H3K27M-mutant 19; HGG-H3G34R: 2; insufficient material 10. Most tumors remained in the same category. However, 46 (30%) changed histological grade. The majority of cases were reclassified from LGG to pilocytic astrocytoma and HGG to astrocytoma grade IV according to molecular results. One tumor initially diagnosed as grade II, was re-classified as a diffuse midline glioma H3K27M-mutated and in 2 cases previously diagnosed as grade III, the KIAA1549-BRAF presence reclassified them as pilocytic astrocytomas.
• The most relevant molecular alterations that allowed to reclassify pediatric gliomas are the BRAF fusion and the K27M mutation.
• Risk-group classification, prognostication and therapy would have been different at diagnosis in 3 cases.
• Even though the 2016 WHO CNS tumor classification system allowed a more accurate diagnosis and prognostication in a third of cases, in only 3/172 patients there would have been a major impact in prognosis and therapy at diagnosis. Additionally, PD-L1 expression by immunohistochemistry (IHC) of high-grade sarcomas has been associated with a poorer prognosis and overall survival. Our objective was to characterize PD-L1 expression in pediatric AFH and IMT, as this has not been done to date.
PD-L1 Expression in Pediatric Soft
Design: 5 cases from 5 patients with AFH and 9 cases from 7 patients with IMT (total of 14 cases, 12 patients, mean age = 11.2, range 1-17 years) from 1998-2017 were evaluated. Diagnoses of AFH and IMT from whole tissue sections were confirmed by two pathologists. ALK IHC (Leica Biosystems, clone 5A4) was performed on all IMTs. PD-L1 IHC (Cell Signaling, E1L3N on IMT & Ventana, clone SP142 on AFH) was performed on all cases. PDL-1 expression on tumor cells only was scored on a semi-quantitative scale of 0-6 by evaluating extent of membranous expression (0=negative, 1=weak, partial, 2=intermediate, 3=strong, diffuse) and percentage of tumor cell positivity (0=negative, 1=<1% positivity, 2 = > 1-4%, 3 = > 5%). Scoring was independently performed by two pathologists. Frequency of PDL-1 expression was determined. Simple student t-test was used to compare PDL-1 expression in AFH and IMT. Association of ALK and PDL-1 positivity using the fisher's exact test was performed using Simple Interactive Statistical Analysis (SISA).
Results: 7 of 9 cases (78%) of IMT and 4 of 5 cases (80%) of AFH demonstrated PD-L1 expression. ALK was observed in seven of nine (78%) IMT cases. Mean PD-L1 score for IMT was 3.89/6 while AFH was 3.93/6. PD-L1 expression between IMT and AFH exhibited no difference (p = 0.521). ALK and PD-L1 expression were not associated (p = 0.417) and 1/2 of ALK-negative cases expressed PD-L1. Background: Lymphocytic esophagitis (LyE) in children remains poorly understood. Here we report 7 patients diagnosed initially with LyE and, upon follow-up, developed eosinophilic esophagitis (EoE).
Conclusions
Design: All esophageal biopsies performed on children (≤18 years-old) in the last 10 years were reviewed. Cases with ≥20 lymphocytes/highpower field and rare eosinophils (≤2) are included. Demographics, clinical and histological findings were retrieved from pathology reports and medical records in accordance with the institutional research board guidelines. Lymphocytic count was generated by counting the numbers of lymphocytes at 40X in a single hot spot.
Results: The search resulted in 24 patients (age range: 1-17.5 years; mean: 6.9 years). They consisted of 11 males (age range: 1-17.5; mean: 6.9 years) and 13 females (age range: 2-16.5 years; mean: 6.9 years). The most common presentation was dysphagia (33.3%) followed by reflux (29.2%), abdominal pain (29.2%), and nausea and vomiting (8.3%). Esophageal endoscopic findings ranged from normal to erosive esophagitis. Ileal and colonic endoscopy ranged from normal to severe active inflammation.
The mean number of lymphocytes was 40.4 (range 21-71 lymphocytes). There was correlation between the number of lymphocytes and a particular final diagnosis. In addition, there was no difference in the number of lymphocytes between males and females.
Follow-up showed that 7 patients were diagnosed with gastroesophageal reflux disorder, 7 patients with eosinophilic esophagitis, 3 patients with Crohn's disease, 1 patient with celiac disease, 1 patient with ulcerative colitis, and 3 patients with gastritis. Follow-up in 3 patients did not disclose any particular entity and were labeled as having LyE. EoE developed a mean of 17 months (range 13-21 months) after the first endoscopy that showed LyE. This finding highlights the importance of regular endoscopic and histologic followup of patients with LyE.
Conclusions:
We identified PTPs that could modulate differentiation and growth of NB cells and found an association between PTPN1 and DUSP5 high expression NB and poor prognosis. PTPN1 expression correlates with metastasis and poor prognosis in several human cancers, whereas a tumor suppressor role for DUSP5 has been proposed. Our results provide insights into the dynamic expression and potential involvement of PTPs in NB, and identify novel candidate NB prognostic biomarkers, which need to be validated in further work. This may have important clinical implications for a better patient stratification and for the implementation of future novel targeted therapies.
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